$50,000 of HUMACYTE lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Payment for approved medical devices. Payment for approved medical devices. Payment for approved medical devices."
You can find more data on corporate lobbying on Quiver Quantitative.
HUMA Insider Trading Activity
HUMA insiders have traded $HUMA stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $HUMA stock by insiders over the last 6 months:
- BRADY W DOUGAN has made 0 purchases and 3 sales selling 2,241,045 shares for an estimated $3,733,191.
- LAURA E NIKLASON (President, CEO and Director) has made 0 purchases and 3 sales selling 2,241,045 shares for an estimated $3,733,191.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
HUMA Hedge Fund Activity
We have seen 96 institutional investors add shares of HUMA stock to their portfolio, and 69 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HEIGHTS CAPITAL MANAGEMENT, INC removed 4,025,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $8,412,250
- RA CAPITAL MANAGEMENT, L.P. removed 3,312,356 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $6,922,824
- MARSHALL WACE, LLP added 2,590,394 shares (+5308.2%) to their portfolio in Q2 2025, for an estimated $5,413,923
- CITADEL ADVISORS LLC removed 2,287,143 shares (-78.5%) from their portfolio in Q2 2025, for an estimated $4,780,128
- TORONTO DOMINION BANK removed 2,131,390 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,454,605
- CENTERBOOK PARTNERS LP added 2,007,743 shares (+141.1%) to their portfolio in Q2 2025, for an estimated $4,196,182
- MONASHEE INVESTMENT MANAGEMENT LLC removed 2,000,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,179,999
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HUMA Analyst Ratings
Wall Street analysts have issued reports on $HUMA in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 10/13/2025
- D. Boral Capital issued a "Buy" rating on 09/30/2025
- Barclays issued a "Overweight" rating on 08/27/2025
- HC Wainwright & Co. issued a "Buy" rating on 08/12/2025
- Benchmark issued a "Buy" rating on 05/14/2025
To track analyst ratings and price targets for HUMA, check out Quiver Quantitative's $HUMA forecast page.
HUMA Price Targets
Multiple analysts have issued price targets for $HUMA recently. We have seen 6 analysts offer price targets for $HUMA in the last 6 months, with a median target of $4.75.
Here are some recent targets:
- Ryan Zimmerman from BTIG set a target price of $6.0 on 10/13/2025
- Jason Kolbert from D. Boral Capital set a target price of $25.0 on 10/06/2025
- Matt Miksic from Barclays set a target price of $3.5 on 08/27/2025
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $3.0 on 08/12/2025
- Joshua Jennings from TD Cowen set a target price of $3.5 on 08/12/2025
- Bruce Jackson from Benchmark set a target price of $14.0 on 05/14/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
